文献リスト

1）Berger J, Hinglais N. Intracapillary deposits of IgA-IgG. J Urol Nephrol. 1968; 74: 694-5

2）D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000; 36: 227-37

3）Gharavi AG, Yan Y, Scdari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000; 26: 354-7

4）Paterson AD, Liu XQ, Wany K, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007; 18: 2408-15

5）Emancipator SN, Gallo GR, Lamm ME. Experimental IgA nephropathy induced by oral immunization. J Exp Med. 1983; 157: 572-82

6）de Fijter JW, Eijgenraam JW, Braam CA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nepbropathy. Kidney Int. 1996; 50: 952-61

7）Roodnat JI, de Fijter JW, van Kooten C, et al. Decreased IgA1 response after primary oral immunization with live typhoid vaccine in primary IgA nephropathy. Nephrol Dial Transplan. 1999; 14: 353-9

8）Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: Observations in three patients. Kidney Int. 2001; 60: 969-73

9）Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001; 59: 1077-85

10）Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001; 38: 736-43

11）Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int. 2004; 65: 1135-44

12）Komatsu H, Fujimoto S, Hara S, et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol. 2008; 3: 1301-7

13）Floege J, Burg M, Kleim V. Recurrent IgA nephropathy after kidney transplantation: not a benign condition. Nephrol Dial Transplant. 1998; 13: 1933-5

14）Cuevas X, Lloveras J, Mir M, et al. Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation. Transplant Proc. 1987; 19: 2208-9

15）Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation. 1982; 33: 370-6

16）Coppo R, Basolo B, Rollino C. Mediterranean diet and primary IgA nephropathy. Clin Nephrol. 1986; 26: 72-82

17）Kumar V, Sieniawska M, Beutner EH, et al. Are immunological markers of gluten-sensitive enteropathy detectable in IgA nephropathy? Lancet. 1988; 2: 1307

18）Fornasieri A, Sinico RA, Maldifassi P, et al. IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger’s disease). Br Med J. 1987; 295: 78-80

19）Rostoker G, Laurent J, Andre C, et al. High levels of IgA antigliadin antibodies in patients who have IgA mesangial glomerulonephritis but not coeliac disease. Lancet. 1988; 1: 356-7

20）Pierucci A, Fofi C, Bartoli B, et al. Antiendomysial antibodies in Berger’s disease. Am J Kidney Dis. 2002; 39: 1176-82

21）Coppo R, Amore A, Gianoglio B, et al. Serum IgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol. 1993; 104: 162-71

22）Suzuki S, Nakatomi Y, Sato H, et al. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet. 1994; 343: 12-6

23）Koyama A, Sharmin S, Sakurai H, et al. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int. 2004; 66: 121-32

24）Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005; 16: 2088-97

25）Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980; 66: 1432-6

26）Tomino Y, Endoh M, Nomoto Y, et al. Immunoglobulin A1 and IgA nephropathy. N Engl J Med. 1981; 305: 1159-60

27）Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. 2004; 65: 1544-7

28）Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007; 71: 1148-54

29）Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008; 118: 629

30）Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999; 104: 73-81

31）Novak J, Tomana M, Matousaick K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005; 67: 504-13

32）Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation. J Immunol. 1994; 153: 5247-55

33）Lai KN, Leung JC, Chan LY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant. 2009; 24: 62-72

34）Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009; 119: 1668-77

35）Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011; 22: 1795-803

36）Gharavi AG, Moldoveanu Z, Wyajj RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008; 19: 1008-14

37）Li GS, Zhu L, Zhang H, et al. Variants of the ST6GALNAC2 promoter influence transcriptional activity and contribute to genetic susceptibility to IgA nephropathy. Hum Mutat. 2007; 28: 950-7

38）Li GS, Zhang H, Lv JC, et al. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 2007; 71: 448-53

39）Yamada K, Kobayashi N, Ikeda T, et al. Down-regulation of core 1 β1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010; 25: 3890-7

40）Horie A, Hiki Y, Odani H, et al. IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis. 2003; 42: 486-96

41）Inoue T, Sugiyama H, Hiki Y, et al. Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol. 2010; 136: 447-55

42）Novak J, Moldoveanu Z, Julian BA, et al. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: Role of mucosal immune system. In: Harabuchi Y, editor. Adv Otorhinolaryngol: Recent Advances in Tonsils and Mucosal Barriers of the Upper Airways. vol 72. Basel: Karger; 2011. p. 60-3

43）Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des. 2006; 12: 4203-13

44）Kataura A, Tsubota H. Clinical analyses of focus tonsil and related diseases in Japan. Acta Oto-Laryngologica. 1996; (523, supplement): 161-4

45）Ono T, Jono M, Kito M, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Oto-Laryngologica. 1983; 401: 12-6

46）Noda K, Kodama S, Suenaga S, et al. Tonsillar focal infectious disease involving IgA nephropathy, pustulosis, and ossification. Clin Exp Nephrol. 2007; 11: 97-101

47）Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11: 373-84

48）Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001; 2: 675-80

49）Suzuki H, Suzuki Y, Yamanaka T, et al. Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23. J Am Soc Nephrol. 2005; 16: 1289-99

50）Okazaki K, Suzuki Y, Otsuji M, et al. Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol. 2012; 23: 1364-74

51）Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008; 19: 2384-95

52）Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 2001; 22: 78-83

53）Ashkar AA, Rosenthal KL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med. 2002; 2: 545-56

54）Bene MC, Faure G, Hurault de Ligny B, et al. Immunoglobulin A nephropathy. Quantitative immunohistomorphometry of the tonsillar plasma cells evidences an inversion of the immunoglobulin A versus immunoglobulin G secreting cell balance. J Clin Invest. 1983; 71: 1342-7

55）Masuda Y, Tamura S, Sugiyama N. The effect of tonsillectomy and its postoperative clinical course in IgA nephropathy with chronic tonsillitis. Adv Otorhinolaryngol. 1992; 47: 203-7

56）Sato M, Hotta O, Tomioka S, et al. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy. Nephron Clinical Practice. 2003; 93: 137-45

57）Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999; 51: 147-52

58）Piccoli A, Codognotto M, Tabbi MG, et al. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant. 2010; 25: 2583-9

59）Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol. 2007; 27: 170-5

60）Miura N, Imai H, Kikuchi S, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009; 13: 460-6

61）Ibels LS, Gyory AZ, Caterson RJ, et al. Recognition and management of IgA nephropathy. Drugs. 1998; 55: 73-83

62）Sato D, Suzuki Y, Kano T, et al. Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid therapy in IgA nephropathy patients. Nephrol Dial Transplant. 2011; 27: 1090-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp